tradingkey.logo
tradingkey.logo
Search

Perspective Therapeutics Inc

CATX
Add to Watchlist
3.630USD
+0.155+4.48%
Close 07/02, 13:00ETQuotes delayed by 15 min
413.88MMarket Cap
LossP/E TTM

TradingKey Stock Score of Perspective Therapeutics Inc

Currency: USD Updated: 2026-07-02

Key Insights

Perspective Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 122 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.38.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Perspective Therapeutics Inc's Score

Industry at a Glance

Industry Ranking
122 / 387
Overall Ranking
247 / 4565
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Perspective Therapeutics Inc Highlights

StrengthsRisks
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Growing
The company is in a growing phase, with the latest annual income totaling USD 884.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 884.00K.
Fairly Valued
The company’s latest PE is -2.60, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 61.79M shares, increasing 3.74% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 24.10K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.47.

Analyst Rating

Based on 14 analysts
Buy
Current Rating
12.385
Target Price
+257.94%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Perspective Therapeutics Inc?

The TradingKey Stock Score provides a comprehensive assessment of Perspective Therapeutics Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Perspective Therapeutics Inc’s performance and outlook.

How do we generate the financial health score of Perspective Therapeutics Inc?

To generate the financial health score of Perspective Therapeutics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Perspective Therapeutics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Perspective Therapeutics Inc.

How do we generate the company valuation score of Perspective Therapeutics Inc?

To generate the company valuation score of Perspective Therapeutics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Perspective Therapeutics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Perspective Therapeutics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Perspective Therapeutics Inc.

How do we generate the earnings forecast score of Perspective Therapeutics Inc?

To calculate the earnings forecast score of Perspective Therapeutics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Perspective Therapeutics Inc’s future.

How do we generate the price momentum score of Perspective Therapeutics Inc?

When generating the price momentum score for Perspective Therapeutics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Perspective Therapeutics Inc’s prices. A higher score indicates a more stable short-term price trend for Perspective Therapeutics Inc.

How do we generate the institutional confidence score of Perspective Therapeutics Inc?

To generate the institutional confidence score of Perspective Therapeutics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Perspective Therapeutics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Perspective Therapeutics Inc.

How do we generate the risk management score of Perspective Therapeutics Inc?

To assess the risk management score of Perspective Therapeutics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Perspective Therapeutics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Perspective Therapeutics Inc.